Masahide Yazaki

Prof. Masahide Yazaki

Department of Neuro Health Innovation, Institute for Biomedical Sciences, Shinshu University, Matsumoto 390-8621, Japan
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2014 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
DKDai Kishida
Dai Kishida
Akinori NakamuraAkinori Nakamura
Akinori Nakamura
MYMasahide Yazaki
Masahide Yazaki
ATAyako Tsuchiya-Suzuki
Ayako Tsuchiya-Suzuki
MMMasayuki Matsuda
Masayuki Matsuda
SIShu-Ichi Ikeda
Shu-Ichi Ikeda
Introduction: Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease characterized by recurrent self-limiting fever and serositis that mainly affects Mediterranean populations. Many patients with FMF have been reported in Japan due to increasing recognition of this condition and the availability of genetic analysis for the gene responsible, MEFV. The present study was performed to elucidate the clinical characteristics of Japanese FMF patients and to examine the precise genotype-phenotype correlation in a large cohort of Japanese FMF patients. Methods: We analyzed the MEFV genotypes and clinical manifestations in 116 patients clinically diagnosed as having FMF and with at least one mutation. Results: The most frequent mutation in Japanese patients was E148Q (40.2%), followed by M694I (21.0%), L110P (18.8%), P369S (5.4%), and R408Q (5.4%). In contrast, common mutations seen in Mediterranean patients, such as M694V, V726A, and M680I, were not detected in this population. The clinical features with M694I were associated with more severe clinical course compared to those seen with E148Q. P369S/R408Q showed variable phenotypes with regard to both clinical manifestations and severity. Patients with M694I showed a very favorable response to colchicine therapy, while those with P369S and R408Q did not. Conclusions: Clinical features and efficacy of treatment in Japanese FMF patients vary widely according to the specific MEFV gene mutation, and therefore genetic analysis should be performed for diagnosis in cases of Japanese FMF.

16 June 2009 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
ATAyako Tsuchiya-Suzuki
Ayako Tsuchiya-Suzuki
MYMasahide Yazaki
Masahide Yazaki
ANAkinori Nakamura
Akinori Nakamura
KYKazuko Yamazaki
Kazuko Yamazaki
KAKazunaga Agematsu
Kazunaga Agematsu
SIShu-Ichi Ikeda
Shu-Ichi Ikeda
Objective.: Familial Mediterranean fever (FMF) is thought to be a rare disorder in Japan, and the clinical features of Japanese patients with FMF remain unclear. Our aim was to elucidate the clinical characteristics of FMF in Japanese patients.Methods.: We analyzed clinical and genetic data of 80 patients based on the results of a nationwide questionnaire survey and review of the literature.Results.: From clinical findings of 80 Japanese patients, high-grade fever was observed in 98.8%, chest attacks (pleuritis symptoms) in 61.2%, abdominal attacks (peritonitis symptoms) in 55.0%, and arthritis in 27.5%. Twenty-four percent of patients experienced their first attacks before 10 years of age, 40% in their teens, and 36% after age 20 years. Colchicine was effective in many patients at a relatively low dose (< 1.0 mg/day). AA amyloidosis was seen in only 1 patient. Common MEFV mutation patterns were E148Q/M694I (25.0%), M694I alone (17.5%), and L110P/E148Q/M694I (17.5%), and no patient carried the M694V mutation, the most common mutation in Mediterranean patients with FMF.Conclusion.: A larger than expected number of patients with FMF exist in Japan, and the clinical presentation of Japanese FMF patients seems to be relatively milder than those of Mediterranean FMF patients. AA amyloidosis rarely occurs in Japanese patients, probably due to difference in patterns of the MEFV genotype between Japanese and Mediterranean patients.

1 January 2010 in Internal Medicine
Verified
Journal Article
Open access
PDF file
KFKazuhiro Fukushima
Kazuhiro Fukushima
MYMasahide Yazaki
Masahide Yazaki
MNMio Nakamura
Mio Nakamura
Naoki TanakaNaoki Tanaka
Naoki Tanaka
KKKeiko Kobayashi
Keiko Kobayashi
SIShu-Ichi Ikeda
Shu-Ichi Ikeda
Citrin deficiency caused by SLC25A13 gene mutations develops into adult-onset type II citrullinemia (CTLN2) presenting with hepatic encephalopathy. Recent studies have suggested that excessive loading of carbohydrates is harmful in citrin-deficient individuals. Here we report a CTLN2 patient who showed further deterioration of encephalopathy after the employment of conventional low-protein diet therapy for chronic liver failure. Owing to the high carbohydrate content, the conventional low-protein diet therapy should be avoided in patients with hepatic encephalopathy associated with citrin deficiency. In addition, our observation may suggest that carbohydrate-restricted diet in which the content of carbohydrate is below 50% of daily energy intake can have therapeutic efficacy in CTLN2 patients.

12 May 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
MKMichiharu Komatsu
Michiharu Komatsu
Naoki TanakaNaoki Tanaka
Naoki Tanaka
TKTakefumi Kimura
Takefumi Kimura
MYMasahide Yazaki
Masahide Yazaki
SLC25A13 gene mutations are responsible for diseases related to citrin deficiency (CD), such as neonatal intrahepatic cholestasis caused by citrin deficiency and adult-onset type II citrullinemia (CTLN2). From childhood to adulthood, CD patients are apparently healthy due to metabolic compensation with peculiar dietary habits—disliking high-carbohydrate foods and liking fat and protein-rich foods. Carbohydrate overload and alcohol consumption may trigger the sudden onset of CTLN2, inducing hyperammonemia and consciousness disturbance. Well-compensated asymptomatic CD patients are sometimes diagnosed as having non-obese (lean) non-alcoholic fatty liver disease and steatohepatitis, which have the risk of developing into liver cirrhosis and hepatocellular carcinoma. CD-induced fatty liver demonstrates significant suppression of peroxisome proliferator-activated receptor α and its downstream enzymes/proteins involved in fatty acid transport and oxidation and triglyceride secretion as a very low-density lipoprotein. Nutritional therapy is an essential and important treatment of CD, and medium-chain triglycerides oil and sodium pyruvate are useful for preventing hyperammonemia. We need to avoid the use of glycerol for treating brain edema by hyperammonemia. This review summarizes the clinical and nutritional features of CD-associated fatty liver disease and promising nutritional interventions.

Verified
Journal Article
Open access
PDF file
MYMasahide Yazaki
Masahide Yazaki
TYTSUNEAKI YOSHINAGA
TSUNEAKI YOSHINAGA
YSYoshiki Sekijima
Yoshiki Sekijima
F亀Fuyuki 亀谷
Fuyuki 亀谷
NONobuo Okumura
Nobuo Okumura
Hereditary fibrinogen Aα-chain amyloidosis (Aα-chain amyloidosis) is a type of autosomal dominant systemic amyloidosis caused by mutations in fibrinogen Aα-chain gene (FGA). Patients with Aα-chain amyloidosis have been mainly reported in Western countries but have been rarely reported in Asia, with only five patients with Aα-chain amyloidosis being reported in Korea, China, and Japan. Clinically, the most prominent manifestation in Asian patients with Aα-chain amyloidosis is progressive nephropathy caused by excessive amyloid deposition in the glomeruli, which is similar to that observed in patients with Aα-chain amyloidosis in Western countries. In molecular features in Asian Aα-chain amyloidosis, the most common variant, E526V, was found in only one Chinese kindred, and other four kindred each had a different variant, which have not been identified in other countries. These variants are located in the C-terminal region (amino acid residues 517–555) of mature Aα-chain, which was similar to that observed in patients with Aα-chain amyloidosis in other countries. The precise number of Asian patients with Aα-chain amyloidosis is unclear. However, patients with Aα-chain amyloidosis do exist in Asian countries, and the majority of these patients may be diagnosed with other types of systemic amyloidosis.

1 February 2011 in Human Pathology
Verified
Journal Article
Closed access
PDF file
ATAyako Tsuchiya-Suzuki
Ayako Tsuchiya-Suzuki
MYMasahide Yazaki
Masahide Yazaki
F亀Fuyuki 亀谷
Fuyuki 亀谷
YSYoshiki Sekijima
Yoshiki Sekijima
SIShu-Ichi Ikeda
Shu-Ichi Ikeda